Attached files

file filename
10-Q - FORM 10-Q - GALECTIN THERAPEUTICS INCd402747d10q.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR33.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex312.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex321.htm
EX-10.3 - EMPLOYMENT AGREEMENT - GALECTIN THERAPEUTICS INCd402747dex103.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR6.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR9.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR2.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR5.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR3.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR1.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR7.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR8.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR4.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR21.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR14.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR17.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR23.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR29.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR32.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR26.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR18.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR30.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR10.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR24.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR20.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR28.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR13.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR16.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR19.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR27.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR12.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR11.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR25.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR31.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR22.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex322.htm
v2.4.0.6
Loss Per Share
9 Months Ended
Sep. 30, 2012
Loss Per Share
8. Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2012     2011     2012     2011  
     (in thousands, except share and per share amounts)  

Basic and diluted net loss per common share:

        

Net loss applicable to common stockholders

   $ (2,985   $ (2,339   $ (8,173   $ (8,995

Weighted average common shares outstanding – basic and diluted

     15,822        12,353        14,851        11,697   

Net loss per common share – basic and diluted

   $ (0.19   $ (0.19   $ (0.55   $ (0.77

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive during the three and nine month periods ended September 30, 2012 and 2011 are as follows:

 

     September 30,
2012 (shares)
     September 30,
2011 (shares)
 

Warrants to purchase shares of common stock

     7,424,241         6,673,400   

Options to purchase shares of common stock

     3,541,630         3,205,582   

Restricted shares subject to vesting

     —           3,473   

Shares of common stock issuable upon conversion of preferred stock

     2,627,110         2,627,110   
  

 

 

    

 

 

 
     13,592,981         12,509,565